SBRT after chemotherapy for inoperable bile duct cancer
Part of Cancer clinical trials.
This trial tests if a precise type of radiation (SBRT) can help people with inoperable bile duct cancer after they finish chemotherapy. It aims to control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bile duct cancer called perihilar cholangiocarcinoma.
- The cancer is a single tumor that cannot be removed with surgery.
- You have completed at least 4 cycles of chemotherapy with gemcitabine (and possibly immunotherapy).
- Your bilirubin, liver enzymes, and blood counts are within acceptable ranges.
- You are 18 or older, able to care for yourself (ECOG 0-1), and have no serious liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies stereotactic body radiation therapy (high-precision radiation given in a few sessions) for liver metastases when surgery isn’t possible. It may help shrink or control tumors in the liver and delay progression in people whose cancer has not spread outside the liver (or only to areas treated with a curative plan).
This trial tests a new combination of immunotherapy (tislelizumab), radiation, and chemotherapy before surgery for people with bile duct cancer that is hard to remove. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests whether adding an immunotherapy drug (rilvegostomig) to standard chemotherapy before surgery can improve outcomes for patients with early-stage bile duct cancer that can be completely removed. The treatment aims to shrink the tumor and help prevent the cancer from coming back.
Hear when a new Klatskin Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.